After Bloomberg reported, citing people familiar with the probe, that the Federal Trade Commission has been investigating Hims & Hers’ business practices for over a year, the company gave a statement to its investor community Hims House saying: “We’ve seen a rehashed story from Bloomberg about an ongoing FTC inquiry. This is the same inquiry as last year, and as we said then, we support the FTC’s mission to protect consumers and remain committed to best practices in everything we do. We are voluntarily cooperating and providing information in response.” Shares of Hims & Hers are down $1.18 to $45.95 in premarket trading.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HIMS:
- Hims & Hers probed by FTC over cancellation practices complaints, Bloomberg says
- Hims & Hers Stock (HIMS) Tanks on Reports of Year-Long FTC Investigation
- Here’s Why Wall Street Is Cautious on Hims & Hers Health Stock (HIMS)
- Strategic Investments and Market Opportunities Drive Buy Rating for Hims & Hers Health
- AI Analyst Predicts 50% Upside for HIMS Stock While Wall Street Stays Cautious